Loading...
Individual differences in drug metabolism and response hold promise for personalized medicine. In a pilot, prospective, open-label, nonrandomized trial, investigators examined whether an individualized pharmacogenetic algorithm that guided medication selection and monitoring would improve care. Genetic testing of DNA from buccal swabs was provided by a pharmacogenetics company with links to three authors.
All participants, consecutively selected patients with major depressive disorder, were genotyped for three cytochrome P450 (CYP) genes (CYP2D6, CYP2C19, and CYP1A2), which determine poor, intermediate, extensive, or ultrarapid metabolic capacity, and for the long and short forms of the serotonin transporter gene (SLC6A4) and a serotonin 2A …